Home › Funds › BAKER BROS. ADVISORS LP › CRNX

BAKER BROS. ADVISORS LP position in CRNX

CRINETICS PHARMACEUTICALS IN

BAKER BROS. ADVISORS LP reported holding 2,351,465 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$88.0M, representing 0.46% of its reported portfolio and ranking #28 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed CRNX holdings in 7 of the last 9 reported quarters, going back to Q2 2024.

Latest position (Q2 2026)2.35M sh
Reported value held$87.99M
Portfolio Weight0.46%
First reportedQ2 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BAKER BROS. ADVISORS LP's CRNX position evolved

BAKER BROS. ADVISORS LP first disclosed a stake in CRNX in Q2 2024 at 103,927 shares (US$4.7M). The position peaked in Q2 2026 at 2,351,465 shares, worth US$88.0M. Across 7 filings, BAKER BROS. ADVISORS LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 2,351,465 shares valued at US$88.0M. Notable position changes include a 489% increase in Q4 2025, a 43% increase in Q1 2026.

Quarter by quarter

QuarterSharesValueChange
Q2 2024 103.93K $4.65M New
Q3 2024 103.93K $5.31M Hold
Q2 2025 280.00K $8.05M New
Q3 2025 280.00K $11.66M Hold
Q4 2025 1.65M $76.75M Add
Q1 2026 2.35M $85.41M Add
Q2 2026 2.35M $87.99M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CRNX and 13F data

CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 37 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CRNX

All CRNX fund holders →

FAQ

How long has BAKER BROS. ADVISORS LP held CRNX?

BAKER BROS. ADVISORS LP has disclosed CRNX holdings in 7 of the last 9 reported quarters, going back to Q2 2024.

What is BAKER BROS. ADVISORS LP's current position in CRNX?

As of Q2 2026, BAKER BROS. ADVISORS LP holds 2.35M shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $87.99M, representing 0.46% of its reported portfolio and ranking #28.

Has BAKER BROS. ADVISORS LP been buying or selling CRNX?

In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in CRNX. The position peaked in Q2 2026 at 2.35M shares.

Which other funds hold CRNX?

Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., DRIEHAUS CAPITAL MANAGEMENT LLC, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.